With the walls of psychedelic prohibition coming down, how does a company like Numinus assemble the right researchers and personnel to get to that next level?
Payton Nyquvest, CEO, joined to talk about strategy and the opportunities they provide to acquire top talent that include Dr. Evan Wood, a global celebrated researcher.
Nyquvest also discussed how last month Numinus became the first publicly-traded company permitted to produce and extract psilocybin from mushrooms. Nyquvest outlines why that’s such a big deal for current and future investors.
* In accordance with an executed agreement between The Dales Report and Numinus Wellness, The Dales Report is engaged with the aforementioned on a 12-month contract for $10,000 per month, with the purpose of publicly disseminating information pertaining to Numinus Wellness via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.